Deck Bio's Multi-Target Engager Aims to Crack Solid Tumor Code

CAMBRIDGE, Mass. – April 20, 2026 – By Anthony Hughes

Biotechnology firm Deck Bio today unveiled promising preclinical data for its lead cancer therapy, DBXO-1, at the American Association for Cancer Research (AACR) Annual Meeting. The results suggest the company may be on a path to solving one of the most stubborn challenges in oncology: making potent immunotherapies work effectively and safely against solid tumors.

While T cell engaging therapies have revolutionized the treatment of blood cancers, their success in solid tumors like lung or stomach cancer has been severely limited. These complex, heterogeneous cancers have proven adept at evading therapies that rely on a single target. Deck Bio's DBXO-1 is engineered with a novel strategy to outsmart the cancer, using a single molecule to recognize and attack multiple targets on tumor cells simultaneously.

A Multi-Pronged Attack on Solid Tumors

The core challenge in treating solid tumors with T cell engagers lies in their diversity. A tumor is not a uniform mass of identical cells; it's a heterogeneous collection where the expression of any single target antigen can vary widely from cell to cell. A therapy aimed at one marker may kill some cancer cells but leave others untouched, leading to treatment resistance and disease relapse. Furthermore, many potential targets are also present at low levels on healthy tissues, creating a high risk of dangerous off-tumor toxicity.

Deck Bio's approach with DBXO-1 is designed to circumvent these fundamental issues. Instead of targeting a single protein on the cell surface, DBXO-1 is a bispecific T cell engager (TCE) that uses an engineered T cell receptor (TCR) binder. This allows it to recognize and bind to multiple, distinct peptide-major histocompatibility complexes (pMHCs) on the cancer cell surface.

These pMHCs are critical because they act as display windows for the cell's internal contents, presenting fragments of intracellular proteins. This opens up a vast library of potential cancer targets—over 90% of all proteins—that are inaccessible to traditional antibody-based therapies. By engaging multiple pMHC targets with a single therapeutic agent, DBXO-1 creates a denser network of 'attack here' signals for the immune system. This multi-target strategy not only increases the chance of T cells recognizing and killing cancer cells but also makes it significantly harder for the tumor to develop resistance by simply down-regulating a single antigen.

Engineering Precision and Safety

While expanding the target portfolio is powerful, it also raises the stakes for safety. Targeting pMHCs requires exquisite specificity to avoid attacking healthy cells that might present similar-looking peptides. Deck Bio has placed this challenge at the center of its design process with its proprietary dbSCOPE™ platform.

This technology, a sequence-agnostic profiling engine, allows the company to perform deep, peptidome-wide screening for potential off-target interactions. According to the data presented at AACR, DBXO-1 was tested against a massive library of 13,849 peptides known to be presented by healthy tissues. The results showed minimal off-target binding, with a specificity profile the company reports as being comparable to an already approved pMHC-targeting T cell engager.

"Leveraging our dbSCOPE technology, we prioritize specificity as a core design principle for DBXO-1, ensuring highly potent multi-target activity does not come at the expense of off-target toxicity," said Johanna Kaufmann, Ph.D., Chief Scientific Officer of Deck Bio, in a statement accompanying the release.

This precision translates into a highly favorable therapeutic window. Functional assays demonstrated that DBXO-1 was over 1,000 times more selective in its activity against target cells versus off-target cells. This level of selectivity is crucial for developing a therapy that can be administered at a dose high enough to eradicate a tumor while minimizing collateral damage to the patient.

Building a Better, More Durable T Cell Engager

Beyond its innovative targeting mechanism, DBXO-1 incorporates design features aimed at making it a more practical and effective drug. The molecule is built on the company's dbTCE™ format, which is engineered for antibody-like stability and manufacturability. This provides an 'off-the-shelf' solution, avoiding the complex logistics and high costs associated with patient-specific cell therapies like CAR-T.

A key component of this format is the dbTv™ technology, a proprietary method for stabilizing the TCR binder. This stabilization has a dramatic impact on the drug's pharmacokinetics. In preclinical models using humanized mice, DBXO-1 demonstrated an estimated elimination half-life exceeding 7.5 days. This is a significant improvement over many first-generation T cell engagers, which had very short half-lives requiring continuous infusion. A longer half-life allows for more convenient, less frequent dosing—such as a weekly or bi-weekly injection—improving quality of life for patients and ensuring sustained therapeutic pressure on the tumor.

The data also confirmed that DBXO-1 effectively mediates T cell activation and potent, target-dependent killing of cancer cells, with potency levels on par with established benchmarks in the field. Importantly, the therapy showed no alloreactivity against closely related HLA alleles, further reinforcing its highly specific recognition profile and lowering the risk of unintended immune reactions.

Charting the Clinical Path and Market Opportunity

With a robust preclinical data package in hand, Deck Bio is now advancing DBXO-1 toward clinical trials. The company's initial focus will be on biomarker-selected patients in major solid tumor indications, including non-small cell lung cancer and gastroesophageal cancers. These diseases represent a significant unmet medical need, and Deck Bio estimates an addressable population of approximately 120,000 biomarker-positive patients in the first-line metastatic setting across the U.S., Europe, and other key markets.

The biomarker-driven strategy is critical. By pre-selecting patients whose tumors express the specific HLA type and peptide targets recognized by DBXO-1, the company can maximize the probability of clinical benefit and streamline the drug development process.

"These data support our thesis that a multi-target approach can expand the reach of T cell engagers in solid tumors while maintaining a high bar for specificity," said Jack Silberstein, Ph.D., Founder and Chief Executive Officer of Deck Bio. "We are advancing DBXO-1 with a disciplined focus on safety, durability of response, and the potential to treat broader patient populations."

As Deck Bio continues its preclinical safety and efficacy studies, the oncology community will be watching closely. By integrating multi-pMHC targeting, deep specificity profiling, and a durable drug format, the company has developed a compelling strategy that directly addresses the historical failures of T cell engagers in solid tumors and offers a new blueprint for the future of cancer immunotherapy.